Fax: 011 (41) 918209044
Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status
Results from International Breast Cancer Study Group Trial V
Article first published online: 18 MAR 2003
Copyright © 2003 American Cancer Society
Volume 97, Issue 7, pages 1591–1600, 1 April 2003
How to Cite
Spataro, V. J., Litman, H., Viale, G., Maffini, F., Masullo, M., Golouh, R., Martinez-Tello, F. J., Grigolato, P., Shilkin, K. B., Gusterson, B. A., Castiglione-Gertsch, M., Price, K., Lindtner, J., Cortés-Funes, H., Simoncini, E., Byrne, M. J., Collins, J., Gelber, R. D., Coates, A. S. and Goldhirsch, A. (2003), Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status. Cancer, 97: 1591–1600. doi: 10.1002/cncr.11224
- Issue published online: 18 MAR 2003
- Article first published online: 18 MAR 2003
- Manuscript Accepted: 15 NOV 2002
- Manuscript Received: 18 SEP 2002
- National Cancer Institute. Grant Number: CA-75362
- Krebsforschung Schweiz, Breakthrough Breast Cancer. Grant Number: AKT 302
- breast carcinoma;
- adjuvant chemotherapy;
- predictive factors
The objective of this study was to clarify the prognostic and predictive value of immunoreactivity for the cyclin-dependent kinase inhibitor p27(Kip1) in patients with early-stage breast carcinoma and to investigate its relation with clinicopathologic features and other markers.
Immunoreactivity for p27 protein was analyzed on tumor slides from 461 patients who were enrolled in the International Breast Cancer Study Group (IBCSG) Trial V (median follow-up, 13 years), including 198 patients with lymph node negative disease and 263 patients with lymph node positive disease. Tumors with < 50% immunoreactive neoplastic cells were considered low expressors. Immunoreactivity for p27 was correlated with several clinicopathologic characteristics. Disease free survival (DFS) and overall survival were analyzed according to p27 immunoreactivity and treatment group.
In the lymph node negative population, decreased p27 immunoreactivity was associated with higher tumor grade (P = 0.001) and HER-2/neu overexpression (P = 0.04). In the lymph node positive population, low p27 expression was associated with higher tumor grade (P = 0.01), low expression of thymidylate synthase (P = 0.001), and higher Ki-67 expression (P = 0.007). DFS was not significantly different according to p27 status in either lymph node negative patients (10-year DFS: low p27 expression, 53% ± 5%; high p27 expression, 55% ± 5%) or in lymph node positive patients (10 year DFS: low p27 expression, 33% ± 4%; high p27 expression, 32% ± 4%). However, in the lymph node negative population, the benefit of one course of perioperative chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil was confined exclusively to patients with tumors that showed reduced p27 immunoreactivity (P = 0.03; test for interaction).
This analysis indicates that p27 immunoreactivity has little if any prognostic value in patients with early-stage breast carcinoma. However, these findings suggest that, in patients with breast carcinoma who have negative lymph node status, reduced p27 immunoreactivity is associated with HER-2/neu overexpression and may be predictive of a benefit from the early administration of adjuvant chemotherapy. Cancer 2003;97:1591–600. © 2003 American Cancer Society.